Microbiota  Intestinal y Cáncer

Evelyn Paola Frias-Toral; Dolores Rodriguez-Veintimilla

doi:10.35454/rncm.v4n1.175

Evelyn Paola Frias-Toral Universidad Católica Santiago de Guayaquil https://orcid.org/0000-0002-2228-0141
Dolores Rodriguez-Veintimilla, DR Clinical Nutrition and Dietetics Service, SOLCA Guayaquil, Ecuador. https://orcid.org/0000-0001-7030-0461

DOI: https://doi.org/10.35454/rncm.v4n1.175

Palabras clave: Microbiota, Cáncer, Salud, Enfermedad

Resumen

La microbiota es el conjunto de microorganismos localizado en diferentes sitios del cuerpo. Aquellos que se encuentran en el intestino tienen un rol esencial, debido a la estrecha relación que tienen con la salud y la enfermedad, en especial el cáncer. Conocer qué microorganismos pueblan el tracto gastrointestinal y sus funciones, qué ocurre cuando se altera su composición, así como identificar su relación con una microbiota saludable para la prevención del desarrollo de tumores, o cómo se vincula la alteración de la microbiota con el desarrollo de tumores merece especial atención.

Descargas

La descarga de datos todavía no está disponible.

Citas

Korecka A, Arulampalam V. The gut microbiome: scourge, sentinel or spectator? J Oral Microbiol. 2012;4:9367. doi: 10.3402/jom.v4i0.9367.

Brandi G, Frega G. Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments. Int J Mol Sci. 2019;20(11):2699. doi: 10.3390/ijms20112699.

Whitman WB, Coleman DC, Wiebe WJ. Prokaryotes: the unseen majority. Proc Natl Acad Sci USA. 1998;95(12):6578-83. doi: 10.1073/pnas.95.12.6578.

Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524-48. doi: 10.1001/jamaoncol.2016.5688.

Ashford NA, Bauman P, Brown HS, Clapp RW, Finkel AM, Gee D, et al. Cancer risk: Role of environment. Science. 2015;347(6223):727. doi: 10.1126/science.aaa6246.

Zhang Y-J, Li S, Gan R-Y, Zhou T, Xu D-P, Li H-B. Impacts of gut bacteria on human health and diseases. Int J Mol Sci. 2015;16(4):7493-519. doi: 10.3390/ijms16047493.

Goodman B, Gardner H. The microbiome and cancer. J Pathol. 2018;244(5):667-76. doi: 10.1002/path.5047.

Icaza-Chávez ME. Microbiota intestinal en la salud y la enfermedad. Rev. Gastroenterol. Méx. 2013;78(4):240-8. doi: 10.1016/j.rgmx.2013.04.004.

Feng Q, Chen W-D, Wang Y-D. Gut Microbiota: An Integral Moderator in Health and Disease. Front Microbiol. 2018;9:151. doi: 10.3389/fmicb.2018.00151.

Tao J, Li S, Gan R-Y, Zhao C-N, Meng X, Li H-B. Targeting gut microbiota with dietary components on cancer: Effects and potential mechanisms of action. Crit Rev Food Sci Nutr. 2020;60(6):1025-37. doi: 10.1080/10408398.2018.1555789.

Scott AJ, Alexander JL, Merrifield CA, Cunningham D, Jobin C, Brown R, et al. International Cancer Microbiome Consortium consensus statement on the role of the human microbiome in carcinogenesis. Gut. 2019;68(9):1624-32. doi: 10.1136/gutjnl-2019-318556.

Palmer C, Bik EM, DiGiulio DB, Relman DA, Brown PO. Development of the human infant intestinal microbiota. PLoS Biol. 2007;5(7):e177. doi:10.1371/journal.pbio.0050177.

De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA. 2010;107(33):14691-6. doi: 10.1073/pnas.1005963107.

Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci USA. 2010;107(26):11971-5. doi: 10.1073/pnas.1002601107.

DuPont AW, DuPont HL. The intestinal microbiota and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol. 2011;8(9):523-31. doi:10.1038/nrgastro.2011.133.

Magne F, Puchi SA, Carvajal B, Gotteland M. The elevated rate of cesarean section and its contribution to non-communicable chronic diseases in Latin America: The growing involvement of the microbiota. Front Pediatr. 2017;5:192. doi: 10.3389/fped.2017.00192.

Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA. 2006;103(33):12511-6. doi: 10.1073/pnas.0601056103.

Vaishnava S, Behrendt CL, Ismail AS, Eckmann L, Hooper LV. Paneth cells directly sense gut commensals and maintain homeostasis at the intestinal host-microbial interface. Proc Natl Acad Sci USA. 2008;105(52):20858-63. doi: 10.1073/pnas.0808723105.

Pereira ICMDS, Ferreira RK, Midori CP, Caldas FLF, Darrieux M, Manzano PT. Childhood obesity and Firmicutes/Bacteroidetes ratio in the gut microbiota: a systematic review. Child Obes. 2018;14(8):501-9. doi: 10.1089/chi.2018.0040.

Muscogiuri G, Cantone E, Cassarano S, Tuccinardi D, Barrea L, Savastano S, et al. Gut microbiota: a new path to treat obesity. Int J Obes Suppl. 2019;9(1):10-9. doi: 10.1038/s41367-019-0011-7.

Ley RE, Hamady M, Lozupone C, Turnbaugh PJ, Roy RR, Bircher JS, et al. Evolution of mammals and their gut microbes. Science. 2008;320(5883):1647-51. doi: 10.1126/science.1155725.

Carding S, Verbeke K, Vipond DT, Corfe BM, Owen LJ. Dysbiosis of the gut microbiota in disease. Microb Ecol Health Dis. 2015;26:26191. doi: 10.3402/mehd.v26.26191.

Carabotti M, Scirocco A, Maselli M, Severi C. The gut-brain axis: Interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203-9.

Neuman H, Debelius JW, Knight R, Koren O. Microbial endocrinology: the interplay between the microbiota and the endocrine system. FEMS Microbiol Rev. 2015;39(4):509-21. doi: 10.1093/femsre/fuu010.

Sandrini S, Aldriwesh M, Alruways M, Freestone P. Microbial endocrinology: host-bacteria communication within the gut microbiome. J Endocrinol. 2015;225(2):R21-R34. doi: 10.1530/JOE-14-0615.

Queipo-Ortuño MI, Seoane LM, Murri M, Pardo M, Gomez-Zumaquero JM, Cardona F, et al. Gut microbiota composition in male rat models under different nutritional status and physical activity and its association with serum leptin and ghrelin levels. PLoS One. 2013;8(5):e65465. doi: 10.1371/journal.pone.0065465.

Virchow R. An address on the value of pathological experiments. Br Med J. 1881;2(1075):198-203. doi: 10.1136/bmj.2.1075.198.

Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis. 2011;17(1):362-81. doi: 10.1002/ibd.21403.

Rodríguez D, Frias-Toral E, Santana S. Adjusted requirements for malnutrition of the cancer patient. Rev Oncol Ecu. 2019;29(2):83-96. doi: 10.33821/92.

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883-99. doi: 10.1016/j.cell.2010.01.025.

Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère, Merad M, et al. Cancer and the gut microbiota: An unexpected link. Sci Transl Med. 2015;7(271):271ps1. doi: 10.1126/scitranslmed.3010473.

Wang J-L, Chang C-H, Lin J-W, Wu L-C, Chuang L-M, Lai M-S. Infection, antibiotic therapy and risk of colorectal cancer: A nationwide nested case-control study in patients with Type 2 diabetes mellitus. Int J Cancer. 2014;135(4):956-67. doi: 10.1002/ijc.28738.

Bonnet M, Buc E, Sauvanet P, Darcha C, Dubois D, Pereira B, et al. Colonization of the human gut by E. coli and colorectal cancer risk. Clin Cancer Res. 2014;20(4):859-67. doi: 10.1158/1078-0432.CCR-13-1343.

Davila A-M, Blachier F, Gotteland M, Andriamihaja M, Benetti P-H, Sanz Y, et al. Intestinal luminal nitrogen metabolism: role of the gut microbiota and consequences for the host. Pharmacol Res. 2013;68(1):95-107. doi: 10.1016/j.phrs.2012.11.005.

Yoshimoto S, Mun LT, Atarashi K, Kanda H, Sato S, Oyadomari S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97-101. doi: 10.1038/nature12347.

Rea D, Coppola G, Palma G, Barbieri A, Luciano A, Del Prete P, et al. Microbiota effects on cancer: From risks to therapies. Oncotarget. 2018;9(25):17915-27. doi: 10.18632/oncotarget.24681.

Sheﬂin AM, Whitney AK, Weir TL. Cancer-promoting effects of microbial dysbiosis. Curr Oncol Rep. 2014;16(10):406. doi: 10.1007/s11912-014-0406-0.

Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017;67(4):326-44. doi: 10.3322/caac.21398.

Halazonetis TD. Constitutively active DNA damage checkpoint pathways as the driving force for the high frequency of p53 mutations in human cancer. DNA Repair. 2004;3(8-9):1057-62. doi: 10.1016/j.dnarep.2004.03.036.

Lara-Tejero M, Galán JE. A bacterial toxin that controls cell cycle progression as a deoxyribonuclease I-likeprotein. Science. 2000;290(5490):354-7. doi: 10.1126/science.290.5490.354.

Bergounioux J, Elisee R, Prunier A-L, Donnadieu F, Sperandio B, Sansonetti P, et al. Calpain activation by the Shigella flexneri effector VirA regulates key steps in the formation and life of the bacterium’s epithelial niche. Cell Host Microbe. 2012;11(3):240-52. doi: 10.1016/j.chom.2012.01.013.

Jan G, Belzacq A, Haouzi D, Rouault A, Métivier D, Kroemer G, et al. Propionibacteria induce apoptosis of colorectal carcinoma cells via short-chain fatty acids acting on mitochondria. Cell Death Differ. 2002;9(2):179-88. doi: 10.1038/sj.cdd.4400935.

Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, et al. Microbial translocation augments the function of adoptively transferredself/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Investig. 2007;117(8):2197-204. doi: 10.1172/JCI32205.

Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow S-N, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of adouble-blind, randomised study in young women. Lancet. 2009;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4.

Vivarelli S, Salemi R, Candido S, Falzone L, Santagati M, Stefani S, et al. Gut microbiota and cancer from pathogenesis to therapy. Cancers. ٢٠١٩;١١(1):38. doi: 10.3390/cancers11010038.

Konishi H, Fujiya M, Tanaka H, Ueno N, Moriichi K, Sasajima J, et al. Probiotic-derived ferrichrome inhibits colon cancer progression via JNK-mediated apoptosis. Nat Commun. 2016;7:12365. doi: 10.1038/ncomms12365.

Lenoir M, Del Carmen S, Cortes-Perez N, Lozano-Ojalvo D, Muñoz-Provencio D, Chain F, et al. Lactobacillus casei BL23 regulates Treg and Th17 T-cell populations and reduces DMH-associated colorectal cancer. J Gastroenterol. 2016;51(9):862-73. doi: 10.1007/s00535-015-1158-9.

Iida N, Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science. 2013;342(6161):967-70. doi: 10.1126/science.1240527.

Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF, et al. Intestinal Blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21(8):1373-83. doi: 10.1016/j.bbmt.2015.04.016.

Lu D, Yan J, Liu F, Ding P, Chen B, Lu Y, et al. Probiotics in preventing and treating chemotherapy-induced diarrhea: A meta-analysis. Asia Pac J Clin Nutr. 2019;28(4):701-10. doi: 10.6133/apjcn.201912_28(4).0005.

Zitvogel L, Ma Y, Raoult D, Kroemer G, Gajewski TF. The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies. Science. 2018;359(6382):1366-70. doi: 10.1126/science.aar6918.

Nagano T, Otoshi T, Hazama D, Kiriu T, Umezawa K, Katsurada N, et al. Novel cancer therapy targeting microbiome. Onco Targets Ther. 2019;12:3619-24. doi: 10.2147/OTT.S207546.